loader2
Partner With Us NRI

Global Health Ltd share Price Today

Company details

1,430.05
1,459.00
487.80
1,513.90
6M Return 91.80%
1Y Return 194.06%
Mkt Cap.(Cr) 38,622.05
Volume 221,851
Div Yield 0.00%
OI
-
OI Chg %
-
Volume 221,851

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Healthcare Facilities company Global Health announced Q3FY24 results:

Financial Performance:

  • Total Income: The consolidated total income for Global Health increased by 21% YoY to Rs 8,545 million in Q3FY24.
  • EBITDA: The company's EBITDA saw a substantial rise of 36% YoY, reaching Rs 2,340 million, with EBITDA margins expanding significantly by 305 basis points to 27.4%.
  • Net Profit: Net profit experienced remarkable growth, up by 53% YoY to Rs 1,235 million, while the PAT margins improved from 11.4% to 14.5%.

Operational Highlights:

  • Bed Occupancy: The average occupied bed days increased by 15% YoY, which corresponds to an average occupancy rate of 64% for the quarter.
  • Patient Volume: The company reported a 13% YoY increase in in-patient count and a 20% YoY increase in out-patient count.
  • Average Revenue Per Occupied Bed (ARPOB): ARPOB saw a growth of 4% YoY, reaching Rs 60,571, primarily driven by higher realizations at the Gurugram unit.

Business Growth:

  • Developing Hospitals Performance: Developing hospitals witnessed revenue growth of 33%, contributing Rs 2,742 million, which amounted to 32% of the total revenue share. Their EBITDA contribution increased from 37% to 41%, summing up to Rs 968 million.
  • Matured Hospitals Performance: The matured hospitals also demonstrated strong performance, with a revenue increase of 17% and EBITDA growth of 37%, totaling Rs 5,875 million and Rs 1,484 million respectively.
  • International Patients Revenue: Revenue from international patients rose by 6% YoY to Rs 473 million, owing to increased volume and realization.
  • OPD Pharmacy Business: There was a 28% YoY increase in revenue from the OPD pharmacy business, up from Rs 224 million in Q3 FY23 to Rs 287 million in Q3 FY24.

Strategic Developments:

  • Doctor Onboarding: Medanta onboarded a total of 253 doctors across their facilities during the first nine months of FY24, with 159 in matured hospitals and 94 in developing hospitals.
  • Upcoming Hospital in Noida: Progress on the Medanta Noida hospital is well on track with the superstructure 82% complete and operations expected to start by the end of FY2025.
  • New Joint Venture: Medanta and DLF formed a special-purpose vehicle company, GHL Hospital Limited, to construct and operate a super-specialty hospital in South Delhi.

Pankaj Sahni, Group CEO, and Director, said: "I am pleased to report that Medanta has delivered strong year-on-year performance during the quarter ended December 31, 2023. In Q3FY24, both our matured and developing units delivered robust revenue growth of 17% and 33% YoY respectively. This growth was primarily driven by increased in-patient volume and improved realization. Our commitment remains unwavering in building a sustainable long-term business model and providing the highest quality care across our key markets."

Result PDF

View Other Company Results

Global Health Ltd shares SWOT Analysis

Strengths (15)

  • Strong Momentum: Price above short, medium and long term moving averages
  • Rising Net Cash Flow and Cash from Operating activity
  • Company with high TTM EPS Growth

Weakness (2)

  • MFs decreased their shareholding last quarter
  • Decline in Net Profit (QoQ)

Opportunity (2)

  • Highest Recovery from 52 Week Low
  • RSI indicating price strength

Threats (3)

  • Promoter decreasing their shareholding
  • High PE (PE > 40)
  • Increasing Trend in Non-Core Income

Resistance and support

R1 1,454.9
R2 1,471.4
R3 1,483.9
Pivot

1,442.48

S1 1,426.0
S2 1,413.5
S3 1,397.0
EMA SMA
1,374.8
1,307.2
1,195.3
1,016.9
1,376.0
1,337.1
1,183.8
964.6
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
JM FINANCIAL INSTITUTIONAL SECURITIES LIMITED Bulk Purchase 2024-02-14 1315.22 3000000 BSE
RJ CORP LIMITED Bulk Purchase 2024-02-14 1315 2882203 BSE
JM FINANCIAL INSTITUTIONAL SECURITIES LIMITED Bulk Sell 2024-02-14 1315.05 3000000 BSE
Name Category Shares
NARESH TREHAN PROMOTER 33.04%

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Global Health Ltd Stocks COMPARISON

Financials( in Cr) Global Health Ltd Apollo Hospitals Enterprise Ltd Max Healthcare Institute Ltd Fortis Healthcare Ltd Narayana Hrudayalaya Ltd
Price 1,438.40 6,384.10 803.45 444.85 1,266.55
% Change -0.28 1.60 -0.93 -1.14 0.31
Mcap Cr 38,622.05 91,793.78 78,088.27 33,584.31 25,883.34
Revenue TTM Cr 2,694.25 16,612.50 4,831.37 6,537.06 4,524.77
Net Profit TTM Cr 326.08 887.50 1,103.51 632.98 606.57
PE TTM 85.69 114.25 74.72 63.51 33.45
1 Year Return 194.06 45.12 78.62 67.65 63.89
ROCE 16.49 14.16 13.85 7.51 29.27
ROE 16.13 15.04 16.12 6.79 33.51
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 2,428.21 Cr FV: 2.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 24,099.58 -5,458.99
LAST 3M 84,754.55 29,178.29
LAST 6M 143,739.62 78,000.86
LAST 12M 219,418.49 195,628.89

Global Health Ltd Information

Stock PE (TTM)
85.69
Promoter Holding
33.04%
Book Value
98.8482
ROCE
16.49%
ROE
16.13%
Description
  • Global Health Limited (GHL) was incorporated as `Global Health Private Limited` on August 13, 2004 at New Delhi, India as a Private Limited Company. The Company converted into a Public Limited Company and name of the Company was changed to `Global Health Limited` dated August 11, 2021 issued by the RoC. Presently, the Company is engaged in the business of providing healthcare services. The Company was founded by Dr. Naresh Trehan, a world-renowned cardiovascular and cardiothoracic surgeon. The Company is one of the largest private multi-speciality tertiary care providers operating in the North and East regions of India in terms of bed capacity with key specialties of cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopaedics, liver transplant, and kidney and urologoly. Under the "Medanta" brand, it has a network of 5 hospitals currently in operation including, Gurugram, Indore, Ranchi, Lucknow and Patna and one hospital in Noida, which is under construction. As at June 30, 2022, the Company provide healthcare services in over 30 medical specialties and is engaged over 1,300 doctors led by experienced department heads and, spanning an area of 4.7 million sq. ft., their operational hospitals have 2,467 installed beds to serve Indian and international patients. In November 2009, the Company opened its flagship hospital in Gurugram. In 2015, its subsidiary, Global Health Patliputra Private Limite (GHPPL), entered into a Concession Agreement with Governor of Bihar for the development, operation and maintenance of a proposed hospital on public-private partnership at Patna. In 2019, it commenced operations of new hospital at Lucknow. In 2020, Patna hospital`s outpatient department facility was launched and the inpatient department facility of its Patna hospital was inaugurated in October 2021, which commenced operations during year 2022. The Company has taken in-house facility and operate pharmacies at its Gurugram, Lucknow, Indore and Ranchi hospitals as well as launched an outpatient department pharmacy at South Delhi clinic in year 2021 and launched outpatient department pharmacy at South Delhi clinic at Patna hospital in year 2022. As at June 30, 2022, it had 200 installed beds and employed over 50 doctors across key specialties such as neuroscience and cardiac sciences. Patna hospital had 228 installed beds and employed over 125 doctors as at June 30, 2022 and is designed to accommodate over 500 beds. In the Board Meeting dated 25 January 2021, the Board of Directors of the Holding Company have approved capital raising comprising of fresh issue and offer for sale of equity shares by the existing shareholders through an Initial Public Offering (IPO) The Company came out with a public issue during November, 2022 by raising Rs. 2205.57 crores through fresh issue amounting to Rs. 500 crores and offer for sale amounting to Rs. 1705.57 crores. The Company`s Lucknow hospital added 191 beds in FY23, including over 90 critical care beds. Lucknow Hospital further added 7 new OTs and have hired over 50 senior clinicians. Towards the end of FY 2023, Lucknow Hospital commissioned the Siemens Varian EDGE Radiation Oncology machine - the first in North India - as well as set up a dedicated e-ICU Command Centre to assist in remote critical care management. The Company`s Patna hospital added over 100 beds and 35 doctors in FY23. In FY23, the Company introduced a new 300- bed hospital project in Indore. It started Medanta Labs in January 2023. During the year 2022-23, GHL Pharma was incorporated as a wholly-owned subsidiary on June 29, 2022.

Registered Address

Medanta-Mediclinic, E-18 Defence Colony, New Delhi, New Delhi, 110024

Tel : 91-124-4834060
Email : compliance:medanta.org
Website : http://www.medanta.org
Registrar

KFin Techologies Ltd

AGM Date (Month) : Sep
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 543654
NSE Code : MEDANTA
Book Closure Date (Month) :
BSE Group : A
ISIN : INE474Q01031

FAQ’s on Global Health Ltd Shares

You can buy Global Health Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Global Health Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Apr 25, 2024 04:03 PM the closing price of Global Health Ltd was ₹ 1,438.40.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Apr 25, 2024 04:03 PM, the market cap of Global Health Ltd stood at ₹ 38,622.05.

The latest PE ratio of Global Health Ltd as of Apr 25, 2024 04:03 PM is 85.69

The latest PB ratio of Global Health Ltd as of Apr 25, 2024 04:03 PM is 0.07

The 52-week high of Global Health Ltd share price is ₹ 1,513.90 while the 52-week low is ₹ 487.80

Download Our

Download App
market app